XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
Key Highlights
- ➤Jan-Paul Simard elected Co-CEO alongside Sushma Shivaswamy, effective Oct. 23, 2026
- ➤Sushma Shivaswamy became interim CEO in December 2025 after John Simard retired
- ➤Jan-Paul Simard joined XBiotech in 2012 and moved to clinical development in 2020
Expert Statements
Tevi Troy, Director of XBiotech
“On behalf of the Board of Directors, we are excited to announce Dr. Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers,”
Tevi Troy, Director of XBiotech
“Their complementary skill sets, scientific acumen, and shared commitment to our mission position XBiotech to fully realize the potential of our True-Human antibody therapies.”
Sushma Shivaswamy, Co-Chief Executive Officer of XBiotech
“As our industry evolves, so must our approach to leadership,”
Sushma Shivaswamy, Co-Chief Executive Officer of XBiotech
“Appointing Jan-Paul Simard as Co-CEO reflects our commitment to staying proactive, adaptive, and relentlessly focused on execution. He brings a distinct perspective and operational continuity that strengthens our decision-making. I look forward to working side-by-side to deliver lasting value to our patients and shareholders”
Jan-Paul Simard, Co-Chief Executive Officer of XBiotech
“It is an honour to step into this leadership role at such a pivotal moment for XBiotech, especially in tandem with a scientist as accomplished as Dr. Shivaswamy,”
Jan-Paul Simard, Co-Chief Executive Officer of XBiotech
“Her leadership as interim CEO has positioned the company to capitalize on its pipeline of drug candidates, and I look forward to partnering with her and our talented team to advance new therapies.”
AUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma Shivaswamy, effective Oct. 23, 2026.
“On behalf of the Board of Directors, we are excited to announce Dr. Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers,” said Director Tevi Troy. “Their complementary skill sets, scientific acumen, and shared commitment to our mission position XBiotech to fully realize the potential of our True-Human antibody therapies.”
Get started
Create a free account to read the full story.